Abstract:Introduction Patients (pts) with systemic peripheral T/NK-cell lymphomas can have cutaneous involvement and their outcomes data are limited in the modern era. We aimed to retrospectively analyse pts who had T/NK-cell lymphomas with cutaneous involvement - PTCL-NOS or extranodal NK/T-cell lymphoma (ENKTL). We excluded cases if they ever had diagnosis of any Primary cutaneous T-cell lymphomas. Methods We conducted a retrospective study of pts with a histopathological diagnosis of T/NK-cell lymphoma established between 2002 and 2022 and identified from the Lymphoma Outcome Database at our center. Pts with a specific diagnosis of PTCL-NOS and ENKTL according to the WHO classification were included if they had biopsy proven involvement of skin. These pts were retrospectively assessed for demographic, clinical, laboratory data, pathology variables, response to treatment and survival outcomes. Fisher's exact test or Chi-square test was used to evaluate the association between two categorical variables. Kaplan-Meier method was used to estimate the time-to-event endpoints including progression-free survival (PFS) and overall survival (OS). Patients without progression or death were censored at the last follow-up date. Appropriate approval was gained from our institution's IRB. RESULTS A total of 356 pts with cutaneous involvement by T/NK-cell lymphoma were analyzed and on further review 45 pts were found to meet the diagnosis of PTCL-NOS ( n=29) or ENKTL ( n=16) with histologically proven cutaneous/subcutaneous involvement according to WHO guidelines. The median follow-up time was 14.5 months (range: 1.84-128.6 months). Twenty-three (51%) pts were men and 22 (49%) women. Median age at diagnosis was 56 years (range, 46-66), with 60% pts less than 60 years old. Thirty (70%) pts were diagnosed as having stage IV disease per Ann Arbor classification. Seven (28%) pts had involvement of an extranodal site other than skin. ECOG PS was 0 in 75% of evaluable pts. Among PTCL-NOS pts, 14/23 (48%) neoplasms were CD4+, 5 (17%) were CD8+; 5 were TCR-gamma+ and 6 pts were TCR-beta+. Of the samples evaluated, CD30 was expressed in 14/28 (50%) cases of PTCL-NOS and 6/12 (50%) of ENKTCL. Bone Marrow involvement was present in 10% of pts. There was no standard frontline systemic therapy approach in this cohort. CHOP-based therapy was used in 15/29 (52%) pts with PTCL-NOS; 8/16 (50%) pts with ENKTL while received asparaginase base therapy. No pts received frontline radiation in the advanced stage setting. Among the 33 evaluable pts in the cohort, the rate of OR to the 1st line treatment was 57.6% (95% CI: 39.2 ~ 74.5%). The rate of CR to the 1st line treatment was 54.5% (95% CI: 36.4 ~ 71.9%). Among PTCL-NOS pts, 12/20 (60%) achieved CR, whereas in ENKTL pts 6/13 (46%) achieved CR to frontline treatment. Fifteen (30%) pts in the cohort had primary refractory disease. Seven pts with PTCL NOS had limited cutaneous/ subcutaneous involvement and received only skin directed therapy without systemic therapy. This pt subset had no evidence of progression, a behavior consistent with primary cutaneous PTCL-NOS. Advanced stage disease was the only variable that had an association with response ( p=0.004). In the whole cohort, the 2=year PFS was 28% with a median PFS of 9.07 (95% CI 4.5-21.98) months. For pts with stage I/II disease, the 2-year PFS was 71% ( 95%CI 0.45 - 1 ) with a median PFS of 177.4 months (95%CI -11.79 - NA). For pts with stage III/ IV disease, the 2-year PFS was 14% (95%CI 0.05 - 0.38 ) with a median PFS of 4.8 months (95%CI 3.19 - 11.99)(p=0.0018). In the whole cohort, the 2-year OS was 47% with median OS of 22.67 ( 95%CI 13.53 - NA) months. For pts with stage I/II disease, the median OS was 177.37 months and for pts with stage III/ IV disease, the median OS was 13.63 months (95%CI 11.99 - NA) (p=0.0018 ) CONCLUSION: Cutaneous / subcutaneous involvement is an uncommon occurrence in pts with T/ NK cell lymphoma and is currently not incorporated in any prognostic scoring system. Systemic T/NK- lymphomas with cutaneous involvement have poor prognosis in our series and underscore the importance of considering skin biopsy in pts presenting with suspicious lesions. We hypothesize that the cutaneous/ subcutaneous tumor microenvironment creates an immune privileged site for chemo-refractoriness. A better understanding incorporating a combined modality approach and novel therapies are needed to improve the outcomes for these pts. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools

Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders

Cutaneous/ Subcutaneous Involvement - an Immune Privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.

Chronic lymphoproliferative disorder of natural killer cells-related neurolymphomatosis with severe autonomic dysfunction: a case report

Clinical and genetic profile of Chinese patients with indolent natural killer-cell lymphoproliferative disorder of the gastrointestinal tract

Delayed Diagnosis of T-Cell Prolymphocytic Leukemia: Approach to Chronic Lymphocytosis

Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder

Clinical features and lymphocyte immunophenotyping analysis in primary immunodeficiency patients with non-transplant lymphoproliferative disorders

Primary Nodal Epstein-Barr Virus-Positive T-Cell/NK-Cell Lymphoma: Real-World Experience

Frequent Activating Mutations of JAK-STAT Pathway Genes in Natural Killer Cell Lymphomas

Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma: an International Collaborative Analysis

Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?

Interim Analysis of a Prospective Multicenter Phase II Study for Advanced‐stage or Relapsed/refractory Natural Killer/t Cell Lymphoma

Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders

A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant.

Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia

Central Nervous System Involvement in Extranodal Natural Killer/T-Cell Lymphoma: Case Series

CD3+CD4-CD8+NK- large granular lymphocytosis with neutropenia and evidence for clonality and T-cell receptor gene rearrangement: two pediatric cases

Unraveling the Transcriptional Landscape of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and T-Cell/Histiocyte Rich Large B-Cell Lymphoma: Impact of Tumor Microenvironment and Checkpoint Gene Expression

NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study

Prevalence, clinical features, and survival outcome trends of 627 patients with primary cutaneous lymphoma over 29 years: a retrospective review from single tertiary center in Korea